Meyerviliptin 50mg Meyer-BPC tablets support diets, blood sugar control (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Vildagliptin

Ingredient

Composition informationContent
Vildagliptin50mg

Uses

Indications

Meyerviliptin is indicated for treatment as a supportive drug for diet and exercise to improve blood sugar control in type 2 diabetes patients (T2DM).

Single therapy:

For patients who do not fully control the diet combined with pure exercise and the patient is intolerant or contraindicated with Metformin.

In combination with two drugs

With Metformin in patients who do not fully control blood sugar when using Metformin single therapy with maximum tolerance.

With a sulfonylure (su) when diet, exercise and monotherapy do not bring adequate blood sugar control.

With a thiazolidindion (TZD) when diet, exercise and thiazolidindion does not bring adequate blood sugar control.

In the combination of three drugs

With a sultonylurea and metformin when diet, exercise and dual treatment with these drugs do not bring adequate blood sugar control.

Meyerviliptin is also designated to coordinate with insulin (with or without metformin) when the diet, exercise and stable insulin dose do not bring enough thick blood sugar control.

Pharmacokinus

Vildagliptin, a substance belonging to the pancreatic island enhancement group, is a strong and selective dipeptidyl peptidase-4 inhibitor (DPP-4), which improves blood sugar control. The DPP-4 inhibition of vildagliptin increases the concentration of glp-1 inscription (Glucagon-Like Peptide-1) and GIP (Glucoseedependent insulinotropic polypeptide) endogenous at hunger and after meals.

Use Vildagliptin to inhibit fast and completely active inhibitors of DPP-4. In patients with type 2 diabetes, using vildagliptin leads to inhibition of enzyme activity DPP-4 for 24 hours.

By increasing the endogenous concentration of these hormones, vildagliptin increases the sensitivity of beta cells on glucose, resulting in improving glucose -dependent insulin secretion. Treatment at a dose of 50 - 100 mg/day for type 2 diabetes patients to significantly improve the functional points of the beta cell fall. The degree of improvement of beta cell function depends on the initial degree of decline; In humans without diabetes (normal blood sugar), vildagliptin does not stimulate insulin secretion or does not reduce blood glucose levels.

By increasing the level of endogenous GLP-1 Vildagliptin, alpha cell sensitivity is increased with glucose, resulting in more glucagon secretion that suits the glucose level. The reduction in the secretion of Glucagon inappropriate meals in turn reduces insulin resistance.

Insulin/glucagon ratio in hyperglycemia due to increased hormonal concentration reduces glucose production in the liver at hunger and after meals, leading to reduced blood sugar.

pharmacokinetic

absorption

Vildagliptin is quickly absorbed with peaks in plasma observed after 1.75 hours. Used with food reduces vildagliptin's absorption rate.

Distribution

Vildagiiptin is poorly cohesive with plasma proteins (9.3%). The average distribution of vildagliptin in a stable state after intravenous injection (VSS) is 71 liters suggesting the drug distributed outside the circuit.

Metabolism

Metabolism is the main elimination line of vildagliptin in humans, accounting for 69% of the dose.

Elimination

After taking [14C] -Vildagliptin, about 85% of the dose is excreted in the urine and 15% is found in the feces. Vildagliptin does not change the excretion through the kidney accounts for 23% of the dose after drinking.

Before taking Meyerviliptin 50mg Meyer-BPC tablets support diets, blood sugar control (3 blisters x 10 tablets)

How to use

Meyerviliptin can be used or not food.

The dose of 50 mg should be taken once a day in the morning. The dose of 100 mg should be divided into 2 doses of 50 mg, orally in the morning and evening.

Dosage

Dosage of treatment applies to adults aged 18 and over

Control of the treatment of diabetes should depend on each patient.

Meyerviliptin's recommended dose is 50 mg, one or twice daily.

In single therapy and in coordination treatment with metformin, with a TZD or with insulin (with or without metformin), the recommended dose of Meyerviliptin is 50 mg or 100 mg daily.

In the combination of combination of drugs with a sultonylurea, the recommended dose of vildagliptin is 50 mg once a day, in this patient group, Vildagiiptin 100 mg/day is not more effective than vildagliptin 50 mg, 1 time/day.

In the combination treatment of 3 drugs with Metformin and a sulfonylure, the recommended dose of Vildagliptin is 100 mg daily.

If more intense blood sugar control requires a daily daily vildagliptin dosage, which can be considered for additional diabetes medications such as metformin, a sultonylurea, a thiazolidindion or insulin.

The dose greater than 100 mg is not recommended.

Renal failure: Do not adjust the dose of vildagliptin in patients with mild renal impairment (CLCR> 50 ml/min) in patients with medium or severe renal impairment or end -stage patient (ESRD), the dose of vildagliptin is recommended as 50 mg, 1 time/day.

Hepatic failure: It is not recommended to use vildagliptin for patients with liver failure.

Elderly (65 years old)

No need to adjust the dose in elderly patients.

Children (under 18 years old)

Do not recommend using vildagliptin for children's patients.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when using overdose?

Support treatment.

Vildagliptin cannot be removed by a separation, but the main metabolic substance due to hydrolysis (Lay151) can be removed by hemorrhage.

What to do when forgetting a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not drink twice as prescribed.

Side Effects

When using Meyerviliptin, you may experience unwanted effects (ADR).

Vildagliptin 100 mg daily in combination with Metformin in double studies:

Common, ADR> 1/100

  • Metabolic and nutritious disorders: Hypoglycemia.
  • Body: fatigue

    Common, ADR> 1/100

  • Metabolic and nutritious disorders: Hypoglycemia.
  • Digestive disorders: constipation.

    • Very rare, ADR

  • Respiratory: Upper respiratory infection, rhinitis.

    Common, ADR> 1/100

  • Metabolic and nutritious disorders: weight gain.
  • Metabolic and nutritious disorders: Lower blood.
  • Nervous system disorders: headache, weakness

    Common, ADR> 1/100

  • Nervous disorders: Dizziness.
  • Metabolic and nutrient disorders: Hypoglycemia.
  • Nervous system disorders: headache.
  • Respiratory: upper respiratory infection, rhinitis.

    Common, ADR> 1/100

  • Metabolic and nutritious disorders: Hypoglycemia. Double blind:

    Common, ADR> 1/100

  • Metabolic and nutrient disorders: Hypoglycemia.
  • Nervous system disorders: headache, chills
  • Gastrointestinal disorders: flatulence, diarrhea

    When having side effects of the drug, notify the doctor or pharmacist.

    • Warnings

    Before using the drug you need to read the instructions carefully and refer to the information below.

    Contraindicated

    Meyerviliptin is contraindicated in cases of hypersensitivity to vildagliptin or any excipients of the drug.

    Precautions when used

    Do not use vildagliptin for patients with type 1 diabetes or to treat diabetic metonic acidosis.

    Hepatic failure: It is not recommended to use VLLDAGLIPIN for patients with liver failure.

    Monitoring of liver emyme: It is necessary to perform liver function tests before starting treatment, during treatment every 3 months, in the first year and periodically.

    Heart failure: Not recommended to use in these patients.

    Kidney failure: Precautions when using vildagliptin in patients with end -stage renal disease (ESRD).

    Skin disorders: Skin damage, including blistering and ulcers that have been reported in monkeys in non -clinical poison studies.

    Acute pancreatitis: If suspected of pancreatic inflammation, Vildagliptin must be stopped. If pancreatic inflammation has been identified, Vildagliptin is not treated again, caution in patients with a history of acute pancreatitis.

    Hypoglycemia: Patients who are using vildagliptin combine sulfonylurea may be at risk of hypoglycemia.

    The ability to drive and operate machinery

    No research has been conducted on impact on the ability to drive train and operate machinery. Therefore, patients may be dizzy should avoid driving trains or operating machinery.

    Pregnancy

    Vildagliptin does not cause teratogen on both rats and rabbits. There is no enough experience to use vildagliptin on pregnant women. Therefore, Vildagliptin should not be used during pregnancy unless the benefits gives the mother higher than the potential risk to the fetus.

    Breastfeeding period

    Because it is unclear whildagliptin is excreted in breast milk or not, so it should not be used vilagliptin for breastfeeding women.

    Drug interaction

    Use in combination with pioglitazone, metformin and glyburide: no clinical pharmacokinetic interactions.

    Combined with digoxin, warfarin: There is no clinical pharmacokinetic interaction. However, this has not been proven to the whole community.

    Combined with Amlodipin, Ramipril, Valsartan, Simvastatin: There is no clinical pharmacokinetic interaction when used simultaneously with Vildagliptin.

    Combined with enzyme inhibitors (ACE): may have a high risk of angioedema in patients when used simultaneously.

    As with other oral diabetes drugs, the hypoglycemic effect of Viidagliptin can be reduced by thiazid diuretic, corticosteroids, armored hormones and sympathetic drugs.

    Storage

    Store drugs in dry, temperatures not exceeding 30 ° C, avoiding light.

    Other drugs

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    count views

    Popular Keywords